These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22046967)

  • 41. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Respiratory pathogen spectrum in pulmonary exacerbation of bronchiectasis in adults and its association with disease severity].
    Gao YH; Guan WJ; Zhu YN; Chen RC; Zhang GJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Apr; 42(4):254-261. PubMed ID: 30955282
    [No Abstract]   [Full Text] [Related]  

  • 44. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study.
    Freitas R; Godinho F; Madeira N; Fernandes BM; Costa F; Santiago M; Neto A; Azevedo S; Couto M; Sequeira G; Dias JM; Bernardes M; Miranda L; Pereira JP; Fonseca JE; Santos MJ
    Drugs Aging; 2020 Dec; 37(12):899-907. PubMed ID: 33205322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA; Cameron DR
    J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
    Wendling D; Di Martino V; Herbein G
    J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
    [No Abstract]   [Full Text] [Related]  

  • 49. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
    Régnier-Rosencher E; Farhi D; Lebrun A; Salliot C; Dougados M; Dupin N
    Dermatology; 2012; 224(1):72-83. PubMed ID: 22487697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
    Singh JA
    Curr Rheumatol Rep; 2016 Oct; 18(10):61. PubMed ID: 27613285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.
    Brito-Zerón P; Bosch X; Pérez-de-Lis M; Pérez-Álvarez R; Fraile G; Gheitasi H; Retamozo S; Bové A; Monclús E; Escoda O; Moreno A; López-Guillermo A; Khamashta MA; Ramos-Casals M;
    Semin Arthritis Rheum; 2016 Feb; 45(4):391-9. PubMed ID: 26277577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.
    Cipriani P; Berardicurti O; Masedu F; D'Onofrio F; Navarini L; Ruscitti P; Maruotti N; Margiotta DP; Liakouli V; Di Benedetto P; Carubbi F; Valenti M; Cantatore FP; Afeltra A; Giacomelli R
    Clin Rheumatol; 2017 Feb; 36(2):251-260. PubMed ID: 27783237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Dosage and toxicity of antirheumatic drugs in renal insufficiency].
    Weiner SM; Bergner R
    Z Rheumatol; 2015 May; 74(4):300-9. PubMed ID: 25962451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The perioperative use of biologic agents in patients with rheumatoid arthritis.
    Polachek A; Caspi D; Elkayam O
    Autoimmun Rev; 2012 Dec; 12(2):164-8. PubMed ID: 22522087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.